Programme

All sessions are tentative and subject to change

Tuesday 23 January

09:00 - 19:00

MEDTECH EUROPE WORKING GROUPS

for MedTech Europe members only

19:00 - 20:00

WELCOME COCKTAIL DINNER


Wednesday 24 January

08:45 - 09:15

Exhibition

WELCOME COFFEE AND REGISTRATION


09:15 - 09:45

Main room

OPENING SESSION


09:15 - 19:00

Exhibition

EXHIBITION AND NETWORKING


09:45 - 10:45

Main room

CEO #NOFILTER

Plenary

Global leaders from the field of medical devices, diagnostics and digital health have agreed to sit together and speak openly about the latest trends, challenges and opportunities they're facing. How are they coping with Brexit, the continuous pressure to innovate, service and low-cost models and what do they expect the next disruptive force to be? The audience will have the opportunity to ask direct questions that will be answered with #nofilter

Objectives:

  • To understand the forces shaping the medtech industry
  • To give audience members an opportunity for an unfiltered Q&A with industry leaders

10:45 - 11:30

Main room

IMPACT OF THE NEW IVD REGULATION ON THE INDUSTRY

Regulatory

The new EU Regulations were published in May 2017 and are intended to strengthen patient protection while fostering competitiveness and innovation. The IVD Regulation applies from May 2022 and is a substantial re-writing of the rulebook for industry. In this panel discussion between authorities, we explore the impact this Regulation is starting to have on IVD manufacturers and their supply chains.
Key questions to be addressed include:
- How are companies planning and budgeting for their new responsibilities?
- What are the main challenges that small, medium and large manufacturers foresee?
- To what extent does the new Regulation affect legacy products versus new innovations?
- What benefits do companies expect to derive from the new, modernized rules?

Room 2

CONNECTING TO THE MEDICAL INTERNET OF THINGS

Digital developments

Patient-generated data from connected medical devices, apps and sensors are on the rise. This raises questions about how different devices and datasets will work together to support remote clinical decision-making and seamless patient experiences. The medical "Internet of Things" system is growing and two experts from outside the traditional medtech industry (a chip manufacturer & a healthcare technology provider) will discuss the current state of play as well as opportunities and challenges for the future.

Objectives:

  • To give an overview of the medical Internet of Things and its potential
  • To elaborate on how to build the right foundation that creates a secure, reliable medical Internet of Things (from a hardware and services point of view)
  • To give suggestions to the medtech industry on how to cope with the IoT

Room 3

EUROPEAN COMMISSION AND MEDTECH INDUSTRY: THE POWER OF PARTNERSHIP

Business strategy

The EU commission will present (in addition to the new regulations) different EU initiatives expected to impact access to innovation and awarding value for medical technologies, in an environment where health is a national competence. The initiatives discussed will be the EU Public Procurement Directive (DG Growth); the EU-HTA cooperation for MedTech (there will be a new EC (non)-legislative proposal on table by this time) and Health System Performance (DG Sante). It will not only be update on activities but foster a discussion from a business perspective e.g. how these initiatives could change the business in Europe in the next 5 years (e.g. increase in number of HTA, shift from price only driven to a Value based procurement, increased demand - data requirement, exchange knowledge, measure performance, change in attractiveness of Europe as first market to go to in a frame of better regulations).

Objectives:

  • To discuss how the European Commission is impacting your business
  • To present relevant EU initiatives in HTA, procurement and more
  • To deepen understanding how these initiatives are implemented

Cinema studio

INDIA - PRICING POLICIES FOR MEDICAL TECHNOLOGIES

International

Over the past few years the question around the cost of access to medical technology in India has become a growing concern both politically and in the national media. With a view to address concerns over affordability and patient accessibility to treatment and procedures, the Indian Government's National Pharmaceutical Pricing Authority (NPPA) introduced price control measures for two categories of medical devices (stents and knee implants). It is expected that these measures may be expanded to other categories of medical technology products over the course of the next months.
Understanding the impact of these price control measures for the MedTech Industry as well as better understanding how the situation will evolve in the short to mid-term so as to ensure that industry can be prepared for upcoming challenges in India.

Objectives:

  • Understand the NPPA's objectives and rationale for implementing the price control measures
  • Discuss and exchange views on alternative options to price control measures in India with the NPPA
  • View the next steps in price control policies in India

11:30 - 12:00

NETWORKING BREAK


12:00 - 12:45

Main room

IMPACT OF THE NEW MEDICAL DEVICES REGULATION ON THE INDUSTRY

Regulatory

The new EU Regulations were published in May 2017 and are intended to strengthen patient protection while fostering competitiveness and innovation. The Medical Devices Regulation applies from May 2020 and substantially modernizes and builds on the existing rules. In this panel discussion between authorities, we explore the impact this Regulation is starting to have on medical devices manufacturers and their supply chains.
Key questions to be addressed include:
- How are companies planning and budgeting for their new responsibilities?
- What are the main challenges that small, medium and large manufacturers foresee?
- To what extent does the new Regulation affect legacy products versus new innovations?
- What benefits do companies expect to derive from the new, modernized rules?

Room 2

DIAGNOSTIC INFORMATION: AN UNPOLISHED JEWEL

Business strategy

Healthcare decision-makers rely on swift and accurate information to diagnose and treat patients. The diagnostics industry can be a key source of the medical information essential to optimising patient outcomes.
But is the full potential of diagnostics information being realised?
There is a unique opportunity to enhance the value of diagnostics if we are able to value information. Diagnostics companies have a jewel in their hands and they need to learn how to polish it.

Objectives:

  • To provide an overview of stakeholders' perspectives of the value of diagnostic information.
  • To use a series of examples and case studies to help attendees discover more about the Value of Diagnostic Information concept and opportunities to use it to demonstrate the value.

Room 3

GAMIFICATION IN MEDTECH - READY TO PLAY?

Business strategy

Improving healthcare is not only about developing better therapies, devices and diagnostics. Better outcomes can be achieved by keeping people motivated to follow prescribed treatment. Applied gaming can play a valuable role in this field.
In this session, two experts will discuss the different purposes and approaches of applied gaming in therapy, prevention, recovery and rehabilitation, diagnosis and treatment.
Jurriaan van Rijswijk has been an Applied Game Architect for 20 years and won the ICT Personality of the Year Award in the Netherlands in 2014. He develops game strategies and designs behaviour change interventions using clinically and scientifically-validated games - for which he has also won various awards.
Hannah Rose Thomson holds an instrumental role at the multiple award-winning company Elvie, which specialises in turning "neglected" medical devices into "fashionable" gadgets that women want to use. Its first product, released a year ago, is a pelvic floor exercise tool that connects to a smartphone app to help women strengthen their muscles.

Objectives:

  • To give an overview of the current and future state of play of gaming in healthcare in general and the (potential) role for the medtech industry
  • To elaborate on the implications of gamification in the product development journey

Cinema studio

SME Financial support models : what is at my disposal?

SMEsTrack

This session will address key issues that SMEs are facing when it comes to financial support. We will present and explain the different financing models available and how to use these.

 

12:45 - 13:30

ADVANCED ANALYTICS IN MEDTECH

Sponsored session


McKinseySponsored by McKinsey

FUTURE OF BUSINESS INTERACTION - HELPING HEALTHCARE PROVIDERS AND MEDTECH INDUSTRY TO INTERACT MORE EFFICIENTLY

Sponsored session

Through this session we will elaborate on the current state of business interactions between healthcare providers and the MedTech industry and explore ways to substantially improve them.
Focusing on inefficiencies linked to transaction cost, cost to serve - reflecting complete go-to-market model -, and pricing arrangements, we will discuss the potential of mutually beneficial value creation processes through disruptive solutions.
We conducted a study set up on a pan-European level with the Vision to identify what the future of business interactions in this segment might look like. Our findings show that moving away from inefficient and unsegmented business interactions towards a more segmented approach could be the next catalyst for margins growth through, for instance, integrated information transaction, committed volumes, and innovative value based payment models tailored to respective requirements.

Objectives:

  • To identify current perspective and appetite on disruptive efficiency improvements in business interactions
  • To determine prerequisites for success and existing road-blocks of efficient business interactions
  • To validate initial hypotheses on cost savings on the proposed solution going forward (including annual tracker)
  • To fuel the ongoing discussion around common data and transaction standards and determine who is to further drive improvements.
DeloitteSponsored by Deloitte
 

SPONSORED SESSION

Sponsored session


12:45 - 14:30

NETWORKING LUNCH


14:30 - 15:15

Main room

POWERING A HEALTH SERVICE ON ARTIFICIAL INTELLIGENCE

Plenary

Powerful new apps are turning phones into mobile medical clinics with artificially intelligent medical advisers acting as superhuman doctors that diagnose and treat patients. Ali Parsa believes that artificial intelligence together with increasing advances in medicine will result in globally accessible and affordable healthcare earlier than most people realise. His digital healthcare company babylon recently received a US$60m investment to build the world's most advanced artificial intelligence (AI) platform in healthcare, to support medical diagnosis and predict personalised health outcomes globally.

Babylon's technology, available from any mobile device or connected computer worldwide, has provided accurate, medical advice to over 250,000 people to date. In January 2017, babylon partnered with the NHS in the UK to use the same technology to power an NHS 111 app available to over a million north London residents, in what is the world's largest deployment of AI in healthcare.

Objectives:

  • To give an overview of the current, practical implications of AI in medical diagnosis and treatment
  • To paint a picture of the future of AI-based medical platforms that diagnose and treat patients
  • To discuss how the MedTech industry can best cope with the upcoming changes (i.e. radical system-wide innovation).

15:15 - 16:00

Main room

WHAT'S HAPPENING WITH NOTIFIED BODIES?

Regulatory

Recent years have seen a consolidation in Notified Bodies, all of which will need to be re-accredited and re-designated under the new IVD and Medical Devices Regulations. The vast majority of IVDs and medical devices - both legacy and new products alike - can only be certified to these new Regulations once these Notified Bodies are fully up and running. Moreover, far more IVDs than ever before will need Notified Bodies in the future, and this has prompted concerns that Notified Bodies will face capacity challenges.
By when can industry realistically expect their Notified Bodies to be available?
How should the industry and authorities manage (and plan around) the timing and capacity uncertainties?
What can you do if your Notified Body disappears, or if you’ve never needed one before?
Attend this panel between authorities, Notified Bodies and industry to find out!

Room 3

THE FUTURE OF CYBER WARFARE IN HEALTHCARE

Digital developments

Is your company or health service protected against cyber warfare? In an increasingly digital environment, strong cyber defences are essential to survival.
Lieutenant Colonel, USMC (Retired) Bill Hagestad will elaborate on the future of cyber warfare in healthcare and the implications for the medtech industry from a corporate and product point of view. Mr. Hagestad is an internationally recognized and respected authority on cyber warfare having published three books on the topic and currently leads the cyber & information security engineering development for Smiths-Medical.

Objectives:

  • To elaborate on the current and future state of play of cyber warfare in healthcare with a focus on the MedTech industry.
  • To give a frank assessment of the current preparedness of the MedTech industry and how to cope with future trends.

Cinema studio

SMEs TRACK

SMEsTrack

The SME track will address key issues that SMEs are facing such as the new regulations (IVDR & MDR) and the different financing models and mechanisms.

Hogan Lovells Hogan Lovells

15:15 - 17:15

Room 2

MEAT VALUE-BASED PROCUREMENT: PROTEIN FOR MEDTECH

Market access

Building up on the drive towards value-based healthcare and smarter healthcare procurement, and taking advantage of the framework provided by the EU Public Procurement Directive, MedTech Europe, in partnership with The Boston Consulting Group and procurement experts, have developed the MEAT Value-Based Procurement framework. Its objective is to support healthcare institutions, hospitals, and health and procurement authorities to adopt value-based decision-making in healthcare procurement.
There is now a strong need for education and exposition to the concrete usage of this framework and related Excel tool throughout the different stages of a procurement process. This will be ensured during this session where via a role play, attendees will be asked to take an active part in a procurement process from the shaping of the tender to the award of the contract.

Format: Please note that this session is GENUINELY active. Each participant will be assigned a role (a buyer or a supplier) when they enter the meeting room. Tables of 12 participants will be set up and each person designated as supplier will have a product/solutions (fictional) to sell and each participant designated as buyer will express their needs. The group (per table) will go through the full procurement process.

16:00 - 16:30

NETWORKING BREAK


16:30 - 17:15

Main room

CONNECTING WITH HYPER-ENGAGED HEALTH CONSUMERS

Business strategy

Various organisations have sparked a revolution in healthcare with their community- and science-based platform for patients. The result is that leveraging patient experience and expertise in the design and development of medical products has become the norm.
Critics argue that some players in the healthcare industry are using these platforms as a shrewd tactic to control the conversation. In this session, various experts will discuss the current state of play and what the future is most likely to bring.

Objectives:

  • To explore the role of patients in the design and development of products
  • To examine community- and science-based platforms for patient engagement
  • To debate the ethical aspects of industry-patient interaction on these platforms

Room 3

IVD INDUSTRY, MORE ALTERNATIVE MODELS

Business strategy


 

Cinema studio

SMEs TRACK

SMEsTrack

The SME track will address key issues that SMEs are facing such as the new regulations (IVDR & MDR) and the different financing models and mechanisms.

Hogan Lovells Hogan Lovells

17:15 - 18:15

Main room

HEALTHCARE TECHNOLOGY FUNDING: THE ROLE AND DEMANDS OF PATIENTS

Plenary

Public anger over the cost of healthcare has burned hot for quite some time and it seems that patient advocacy groups have been largely absent from the public debate over funding. Some argue that patient groups should take a public position on affordability because, by avoiding the debate, they are failing in their patient-advocacy duties. In this session, various experts on the topic will elaborate on the role and purpose of patient organisations when it comes to healthcare technology funding and what they expect from industry.

Objectives:

  • To discuss the role that drug funding plays on the agenda of patient advocacy groups
  • To elaborate on the priority setting of patient advocacy groups regarding access and funding (and their interdependent relationship)
  • To determine the current (and ideal) position of industry in working with patient advocacy groups

18:15 - 20:00

NETWORKING COCKTAIL


Thursday 25 January

09:00 - 09:30

WELCOME COFFEE AND REGISTRATION


09:30 - 10:30

Main room

CEO #NOFILTER

Plenary

Global leaders from the fields of medical devices, diagnostics and digital health come together for an open exchange about the latest trends, challenges and opportunities they face. How are they coping with the continuous pressure to innovate, the increased focus on ethics, the demand for new service and low-cost models and the role of Europe and Brexit? And what do they expect the next disruptive force to be? The audience will have the opportunity to ask direct questions that will be answered with #nofilter

Objectives:

  • To understand the forces shaping the MedTech industry
  • To give audience members an opportunity for an unfiltered Q&A with industry leaders

09:30 - 16:00

Exhibition

EXHIBITION AND NETWORKING


10:30 - 11:00

NETWORKING BREAK


11:00 - 11:45

Main room

OUTCOME-BASED FINANCING MODELS: WHO IN THE MEDTECH INDUSTRY CAN RISK IT?

Business strategy

Outcome-based healthcare financing is moving from theory to practice. But are health systems ready to collect outcomes data? And are health authorities and payers willing to pay for outcomes?
This session will explore how outcomes-based financing goes from concept to reality and the role of industry in driving this change. In addition, the roles of large and small companies in this transition will be examined.

Objectives:

  • To provide a brief overview of the relevance of outcomes-based financing and current initiatives in outcomes data collection.
  • To explore the impact of value-based healthcare on reimbursement models
  • To look at how the MedTech business model will be transformed by the shift towards an outcome-based healthcare system

Room 2

ASK THE EXPERTS

Ask the experts

Roundtable discussions designed for smaller groups of 12 people together with 1 leader (expert) focusing on one topic.

Room 3

DATA PROTECTION: THE DARK FORCE FOR HEALTHCARE INDUSTRY?

Business strategy


Cinema studio

SOUTH AFRICA - LOCALIZATION AND REGULATION, IMPACT ON THE MARKET

International

South Africa’s Department of Health has been working on a long awaited dedicated new regulatory framework for medical devices and in vitro diagnostics. The new legislative framework is in place with the publication of a Regulation on 9 December 2016 which is broadly based on guidance and principles of the International Medical Device Regulators Forum (IMDRF) and its predecessor the Global Harmonization Task Force (GHTF). A key new measure has been the formation of the South African Health Products Regulatory Authority which will oversee the medical device market in South Africa but there are still questions as to how this new regulatory body will operate and what the practical implementation of the new law will entail.
At the same time the Government is also aiming at implementing localization measures favoring local manufacturers which raises new challenges and increases the complexity of doing business in South Africa.

Objectives:

  • Understand what the key expected changes to the existing framework are
  • Get insight into the impact the new framework will have on your business organization
  • Next steps and potential industry contribution to future consultations

11:45 - 12:30

Main room

MEDTECH ACCESS MODELS: THE GOOD, THE BAD AND THE UGLY

Market access

The MedTech industry is committed to shifting from a technology-based model to a value-based system. Rather than payment being based upon what can be done but for ever lower prices, a model is emerging that rewards outcome relevant to patients, health professionals and health systems, as well as the economy and wider society.
MedTech Europe is taking a leading role in making this change a reality. At the same time other access models exist in Europe and across the World with their advantages and disadvantages for medical technology industry. Let's debate advantages and disadvantages of these different systems and what they mean for medical technology.

Objectives:

  • To define 'Value': can Professor Michael Porter's definition of Value-Based Healthcare be applied in Europe or do we need a broader view?
  • To debate different access models their advantages and disadvantages

Room 2

ASK THE EXPERTS

Ask the experts

Roundtable discussions designed for smaller groups of 12 people together with 1 leader (expert) focusing on one topic.

Room 3

INTEGRATED OFFERINGS: DOES SIZE MATTER?

Business strategy


Cinema studio

SPOTLIGHT ON USA

International

Medical technology companies are facing a wave of changes that could impact their businesses, including the potential repeal and replacement of the Affordable Care Act, changes in US trade policy, the potential passage of tax reform, continued pressure on pricing and user fee reforms. Many of these changes are interrelated and the impact to a company should be evaluated in total. This workshop will discuss the accomplishments and progress of the Trump Administration’s first year in office and explore changing trade and tax policy with particular focus on the impacts to supply chains, capital investment, and other aspects of operations.

Objectives:

  • Trump Administration Policies and Accomplishments - first year in Office
  • Overview of potential reform and impact on tax and business operations
  • Potential impact on the medical technology industry
  • Next steps

12:30 - 13:15

Main room

SPONSORED SESSION

Sponsored session


Room 3

SPONSORED SESSION

Sponsored session


Cinema studio

SPONSORED SESSION

Sponsored session


12:30 - 13:45

NETWORKING LUNCH


13:45 - 14:30

Main room

THE MEDTECH EUROPE CODE AS A BUSINESS ENABLER

Business strategy

1st January 2018 is a cornerstone date for the implementation of the MedTech Europe Code of Ethical Business Practice. As such, it is the right moment to take stake on:
- where we are, considering in particular the following players: MedTech Europe corporate Members, National Associations, SMEs, impacted stakeholders (e.g. medical societies, customers, PCOs, hospitals);
- what still needs to be done; and
- what were the unexpected challenges;
- what are the new business opportunities (e.g. new business models (e.g. value-based healthcare) emerging at the same time as the Code provides a new way to the relationship with customers, impacting how marketing was done until now).

Room 2

ASK THE EXPERTS

Ask the experts

Roundtable discussions designed for smaller groups of 12 people together with 1 leader (expert) focusing on one topic.

Room 3

MEAT: A NEW PHILOSOPHY FOR MEDTECH SALES

Business strategy

Procurement is the main access path for medical technology. Increasingly, price has become a main driver for making purchasing decisions, with administrators in the driving seat. The EU believes public procurement should apply the most economic advantageous Tendering (MEAT) concept. This is primarily to be achieved by obtaining the best price/quality ratio.
The MedTech industry is ready to embrace value-based procurement with a broad value proposition for all levels and for different stakeholders. This requires companies to rethink the role of their sales organisation and to enhance cooperation between departments. Sales teams need to learn how to define and sell value to different stakeholders rather than focusing only on the product and its features.

Objectives:

  • To present real procurement cases to indicates how this new value proposition can affect the awarding of tenders.
  • To identify critical junctures in the procurement process when the criteria that will be used in decision-making are discussed and who is involved (i.e. in the pre-tendering space).
  • To showcase MEAT Value-Based Procurement as a supportive framework and to raise awareness of how sales organizations can communicate the value proposition.

Cinema studio

BECOMING HACKPROOF IN MEDTECH

Digital developments

In the past three years, the healthcare sector has been hacked more than the financial industry. As hackers increasingly take advantage of historically lax security on embedded devices, defending medical instruments has taken on new urgency. Two experts will elaborate on how to cope with cyber threats from a technical, regulatory and risk management point of view.
Roman Lysecky, a recipient of the prestigious American National Science Foundation Early Career Award and an associate professor in the UA's Electrical and Computer Engineering Department, is building technology that enable medical devices to detect malware and security breaches while continuing to function properly.
Anita Finnegan, Founder and CEO of Nova Leah, worked on a five-year R&D programme at Dundalk Institute of Technology to develop a system to guide medical device manufacturers in the implementation of cybersecurity requirements and best practices over the lifetime of a device in compliance with regulations.

Objectives:

  • To discuss how to cope with cyber threats from a technical and process/regulatory/risk management point of view
  • To give an overview of the current regulatory framework (EU & US), its effectiveness and implications for the industry
  • To provide an overview of the current thinking of cyber security in designing the products and the implications for industry

14:30 - 15:15

Main room

BREXIT: AND NOW WHAT?

International


Room 2

ASK THE EXPERTS

Ask the experts

Roundtable discussions designed for smaller groups of 12 people together with 1 leader (expert) focusing on one topic.

Room 3

A NOVEL AND FRESH VIEW ON TRANSFORMING HEALTH SYSTEMS WITH TECHNOLOGY AND INNOVATION

Digital developments

Dr Mahiben Maruthappu, educated at Oxford, Cambridge and Harvard Universities and the first person from British healthcare to be included in Forbes '30 under 30', will elaborate on how to successfully implement efficiency and innovation into health systems from a theoretical and practical point of view.
Dr Maruthappu is a renowned expert in the field and cofounded the NHS Innovation Accelerator and the NHS Diabetes Prevention Programme, as well as Cera, a technology company transforming social care. He currently also serves on the DigitalHealth.London and NHS Prevention boards.

Objectives:

  • To elaborate on how health systems are successfully integrating efficiency and innovations (opportunities, challenges, hurdles and best practices)
  • To give a frank assessment of the approach of the traditional MedTech players (e.g. Medtronic, J&J) versus the new players such as Cera, Babylon
  • To showcase new innovative (service) models of care such as Cera

Cinema studio

HOW TO MAKE EUROPE GREAT AGAIN FOR MEDTECH INNOVATION

Business strategy

What are the different initiatives in Europe expected to improve the access to innovation and awarding value by the medical technologies. New initiatives and financing schemes for innovation on EU level (e.g. Horizon 2020) and on country level are arising in Europe and they could be future viable solution for the industry and innovation in Europe. Let's discuss "How to make the Europe great again for the medtech innovation".

Objectives:

  • To foster a discussion from a business perspective on how different initiatives and trends in Europe could change the business in Europe in the next 5 years (e.g. increased demand for data, exchange knowledge, measure performance, more transparency across countries)
  • To discuss from market access perspective what could be the solutions to identified barriers for innovation
 

15:15 - 16:00

Main room

DISRUPTIVE HEALTHCARE

Plenary

Disruptive healthcare triggers changes for all healthtech stakeholders. It entails reviewing the old fashion way of doing things and adapting to new networks, new organisational structures, new players... Healthcare in general - and the MedTech industry in particular - can truly benefit from those new perspectives. Find out from Prof. Fitzgerald what disruptive healthcare has in store for you.

16:00 - 16:15

Main room

CONCLUSIONS


© Copyright 2017 - Europa Organisation - All rights reserved